<DOC>
	<DOCNO>NCT01397799</DOCNO>
	<brief_summary>This Phase 1b study determine maximum tolerate dose KX2-391 give once-daily dose , elderly patient acute myelogenous leukemia .</brief_summary>
	<brief_title>Evaluation KX2-391 Elderly Subjects With Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>KX2-391 evaluate Phase 1 dose escalation study patient solid tumor use twice-daily dosing . This study employ Storer 's two-stage design determine maximum tolerate dose KX2-391 mono-therapy , give once-daily oral dose , elderly patient acute myelogenous leukemia ( AML ) refractory decline standard induction therapy . The safety , tolerability , pharmacokinetics activity KX2-391 evaluate .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Written inform consent . Either de novo secondary AML 2008 World Health Organization ( WHO ) classification . A bone marrow biopsy aspirate sample must obtain Day 14 Day 1 , sample must confirm adequate morphologic analysis marrow cellularity blast percentage first dose KX2391 administer . A bone aspirate sample ( without biopsy ) must obtain patient sign inform consent document submit baseline pharmacodynamic assessment . Although usually obtain part baseline assessment marrow biopsy aspirate procedure describe , complete marrow evaluation perform prior patient signing informed consent , dedicate bone marrow aspiration sample perform patient sign inform consent , long preconsent biopsy aspirate procedure do within 14 day first dose KX2391 . Adults age ≥ 60 year age Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Life expectancy least 6 week first day study drug administration Adequate liver function ( AST/ALT &lt; 3 x upper limit normal ( ULN ) , Alk Phos &lt; 2.5 x ULN , Direct Bilirubin &lt; 1.5 x ULN ) Adequate renal function ( serum creatinine &lt; 1.5 x ULN ) Documented QTc ≤ 0.48 second within 14 day first dose KX2391 Subjects acute promyelocytic leukemia ( APL , AML FAB type M3 ) , chronic myelogenous leukemia ( CML ) . Have resolve toxicity previous anticancer treatment investigational agent , hematologic toxicity alopecia , ≤ Grade 1 accord recent CTCAE guideline . Subjects rapidly proliferative AML likely require treatment within next 30 day ( e.g . hydroxyurea ) . Received investigational agent within 5 halflives agent anticipated Cycle 1 Day 1 treatment KX2391 . Have clinical evidence central nervous system involvement AML malignancy . History major surgery upper gastrointestinal tract , history inflammatory bowel disease , malabsorption syndrome , medical condition may interfere oral drug absorption . Uncontrolled hypertension ( time dose ) . Other medical condition , opinion investigator , make undesirable subject participate study . Known history hepatitis B , C , human immunodeficiency ( HIV ) infection . Uncontrolled intercurrent illness include , limited , ongoing active infection . Patients receive intravenous antibiotic infection control may include study . Subjects unwilling unable comply protocol . Subjects take moderate strong CYP450 3A4 modulators , exception fluconazole ( see Appendix 2 list medication currently know moderate strong CYP450 3A4 modulators ) . Subjects safely discontinue medication become eligible trial . Subjects receive azolebased antifungal prophylaxis fluconazole ( see Appendix 2 ) unable switch prophylaxis fluconazole , discontinue antifungal prophylaxis , 7 day prior first day study drug administration . Active cancer , AML , require systemic chemotherapy biological therapy within 6 month study entry . Patients receive hormonal therapy neoadjuvant adjuvant set past 6 month may participate study . Symptomatic congestive heart failure , unstable angina , cardiac arrhythmia . Other condition could jeopardize subject 's ability comply protocol , include , limited , dementia , psychosis , major psychiatric disorder Pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Refractory</keyword>
	<keyword>Elderly</keyword>
</DOC>